苄达赖氨酸滴眼剂治疗白内障的研究

Treatment of senile cataract with Bendazac Lysine eyedrops.

目的:评价苄达赖氨酸滴眼剂对早期老年性皮质性白内障的疗效及不良反应。方法:5个临床试验中心半年内对315例早期老年性皮质性白内障患者575眼作随机双盲临床试验,治疗组216例397眼,对照组99例178眼,治疗组用0.5%苄达赖氨酸滴眼剂3次/日,1～2滴/次,对照组用溶媒液3次/日,1～2滴/次。结果:用药24周治疗组总有效率70.78%,对照组32.58%,P<0.01有显著差异。不良反应以瞬时烧灼感较多见。结论:0.5%苄达赖氨酸滴眼剂是一种安全有效的抗白内障新药。

To evaluate the efficacy and adverse effects of Bendazac Lysine (BDZL) eyedrops 0.5% in the treatment of early senile cataract. Method: A double-blind randomized placebo-controlled study was performed in 5 hospitals on 315 early senile cataract patients (575 eyes) from April to October 1995. 216 patients (397 eyes)received BDZL eyedrops 0.5% and 99 patients(178 eyes)received placebo. Result. 1-2 drops 3 times daily. In the BDZL group the efficacy rate was 70.78%, Whereas in the control group the efficacy rate was 32.58% (P&lt;0.01) . The main adverse effect and in the BDZL group was transient oaclcc irritation. Conclusion. BDZL eyedrops 0.5% is a safe and effective new anticataract drug.